Market capitalization | $599.24m |
Enterprise Value | $-67.63m |
P/E (TTM) P/E ratio | 35.21 |
EV/FCF (TTM) EV/FCF | 0.34 |
EV/Sales (TTM) EV/Sales | -0.38 |
P/S ratio (TTM) P/S ratio | 3.39 |
P/B ratio (TTM) P/B ratio | 0.92 |
Revenue growth (TTM) Revenue growth | 188.33% |
Revenue (TTM) Revenue | $176.66m |
As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.
8 Analysts have issued a Immatics N.V forecast:
8 Analysts have issued a Immatics N.V forecast:
Dec '24 |
+/-
%
|
||
Revenue | 177 177 |
188%
188%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -30 -30 |
72%
72%
|
EBIT (Operating Income) EBIT | -44 -44 |
62%
62%
|
Net Profit | 17 17 |
116%
116%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
Head office | Netherlands |
CEO | Harpreet Singh-Jasuja |
Employees | 618 |
Founded | 2020 |
Website | immatics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.